Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

NCT03618654 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma
Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG: Metformin
BIOLOGICAL: Durvalumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University